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e-mail address: amm-ry@hotmail.comAli M. Al-Halafi, MD, FRCS ⇑AbstractMelanocytoma of the optic disc is a benign melanocytic tumour that rarely causes visual impairment. We report a rare
case of choroidal neovascularization (CNV) in association with optic disc melanocytoma and its response to intravitreal
injection of the anti-vascular endothelial growth factor (VEGF), bevacizumab. The choroidal neovascular membrane
regressed following a single intravitreal bevacizumab injection with formation of a scar. CNV associated with optic disc
melanocytoma is rare. Intravitreal anti-VEGF treatment may be an effective treatment for CNV associated with optic disc
melanocytoma.
Keywords: Anti-VEGF, Bevacizumab, Choroidal neovascular membrane, Melanocytoma, Optic disc
 2013 Saudi Ophthalmological Society, King Saud University. All rights reserved.
http://dx.doi.org/10.1016/j.sjopt.2012.12.002Introduction
Choroidal neovascularization (CNV) consists of growth
of the fibrovascular tissue from the choriocapillaris,
through defects in Bruch’s membrane into subretinal
pigment epithelial space and eventually, into subretinal
space. Common causes of CNV include age-related macu-
lar degeneration (ARMD), high myopia, angioid streaks,
choroidal rupture, posterior uveitis, histoplasmosis, and
birdshot chorioretinopathy.1 CNV is an uncommon compli-
cation of choroidal nevus, melanoma, or melanocytoma.2,3
Anti-vascular endothelial growth factor (VEGF) compounds
have been shown to have a beneficial role in treating
CNV. In this case report, we present the treatment of a
rare case of CNV associated with optic disc
melanocytoma.Case report
A 45-year-old male patient presented with decreased
vision in the right eye for 3 weeks. Best corrected visual
acuity (BCVA) was 20/160 in the right eye and 20/20 in
the left eye. Slit lamp examination was normal and intraoc-
ular pressure (IOP) was 16 mmHg in both eyes. Amsler grid
testing indicated a central sparing relative scotoma in the
temporal visual field of the right eye. Ophthalmoscopy
indicated an optic disc melanocytoma with a yellowish,
elevated, well defined membrane overlying the papilloma-
cular bundle surrounded by haemorrhage (Fig. 1). Fundus
examination of the left eye was normal with no myopic
findings bilaterally.
Fundus fluorescein angiography (FFA) of the right eye
revealed a lacy pattern in the early arterial phase, whiche:
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Figure 1. Melanocytoma of the optic disc with a yellowish, elevated, well
defined membrane overlying the papillomacular bundle surrounded by
haemorrhage in the right eye.
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venous phase (Fig. 2). It was surrounded by a haemorrhage
that blocked fluorescence (Fig. 3A). Optical coherence
tomography (OCT) of the right eye revealed serous detach-
ment of the neurosensory retina and retinal thickness of
515 micron in this area (Fig. 3B).
The patient was diagnosed as a case of melanocytoma of
optic disc with classic juxtafoveal CNV in the right eye. The
patient underwent one injection of intravitreal bevacizumab
1.25 mg in 0.05 ml.Figure 2. Fluorescein angiogram of the right eye showing a lacy pattern in th
the late arteriovenous phase.FFA one month after treatment, showed staining and no
leakage consistent with scarring (Fig. 3C). OCT showed reso-
lution of the serous detachment with retinal thickness of
290 micron in the corresponding area (Fig. 3D). One year
after treatment, there has been no recurrence of the CNV
and vision in the right eye is 20/30.Discussion
Melanocytomas appear as grey to jet-black elevated le-
sions and usually do not exceed one disc diameter in size
on ophthalmoscopy. However, one report presented a lesion
that was six disc diameters in size.4 Melanocytomas are usu-
ally asymptomatic. CNV is rarely associated with melanocy-
toma and can lead to severe visual loss. This lesion can be
differentiated from malignant transformation by the constant
size of the tumour.5 Inflammation or necrosis2 is known to oc-
cur in melanocytoma and can induce rupture of Bruch’s mem-
brane and choroidal neovascularization.
Anti-VEGF compounds are promising treatment modali-
ties for a number of retinal lesions. Bevacizumab is an anti-
body that binds to the VEGF with a direct angiostatic
effect. Good visual outcomes have been reported with
intravitreal bevacizumab for CNV related to ARMD,6 patho-
logical myopia,7 inflammatory and idiopathic membranes.8
Beneficial outcomes with intravitreal bevacizumab for a case
of melanocytoma-associated CNV have been previously re-
ported by Kamisasanuk and colleagues.9 Kamisasanuk and
colleagues’9 report concurs with the outcome in our case.
Our patient had regression of CNV with a single injection,
and there was a functional improvement. Intravitreal bev-
acizumab seems to be an effective treatment modality for
CNV associated with melanocytoma.e early arterial phase, which increased in intensity and showed leakage in
Figure 3. (A) Fluorescein angiogram of the right eye, pre-injection, showing increased intensity and leakage from the CNV in the late arteriovenous
phase with an area of blocked fluorescence. (B) Optical coherence tomography of the right eye, pre-injection, showing subretinal fluid with a retinal
thickness of 565 microns in the area nasal to the fovea. (C) Fluorescein angiogram of the RE one month postinjection showing only staining of the
membrane with surrounding window defects. (D) OCT of right eye one month post-injection showing hyper-reflectivity corresponding to the scar with no
residual fluid and a thickness of 290 microns in the corresponding area.
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